Sign In | 0 items - USD $0.00 | Search | Compare 简体中文

Products Content

Blog

Wild-Type Tau in Alzheimer’s Disease

Brenda Knox | November 25th, 2021 | Scientific Review

Akt Signaling

Akt Signaling, Cell Growth and Survival

Brenda Knox | October 19th, 2021 | Scientific Review

IHC analysis using DNA Damage Antibody, (SMC-155)

Oxidative DNA Damage and its Role in Disease

Brenda Knox | September 17th, 2021 | Scientific Review

Characterizing Pathogenic Protein Aggregates for Utilization as Molecular Tools to Accelerate Neurodegenerative Disease Research

Webinar: Accelerating Neurodegenerative Disease Research with Pathogenic Protein Aggregates

Brenda Knox | September 14th, 2021 | Webinar

Wild Type SOD1 in ALS

The Role of Wild Type SOD1 in ALS

Brenda Knox | September 1st, 2021 | Scientific Review

Targeting Alpha Synuclein Aggregation with CBP/p300 Inhibitors: A Novel Approach in Parkinson’s Disease Therapeutics

Christina Korgiopoulou | August 13th, 2021 | Product Citation Reviews

9th Annual Neuroscience Virtual Conference

9th Annual Neuroscience Virtual Conference

Brenda Knox | August 4th, 2021 | Conferences

Tau Monomers

Targeting Tau Monomers: Potential for Therapeutic Interventions

Brenda Knox | June 28th, 2021 | Scientific Review

Why target Alpha Synuclein Monomers?

Alpha Synuclein Monomers: Why Target Them?

Brenda Knox | June 10th, 2021 | Scientific Review

N terminal acetylated alpha synuclein monomers and fibrils for neurodegenerative disease research

N-terminal Acetylated Alpha Synuclein in Parkinson’s Disease

StressMarq Biosciences | May 13th, 2021 | Scientific Review